 Benzhydryl Compounds
"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
| Descriptor ID |
D001559
|
| MeSH Number(s) |
D02.455.426.559.389.115
|
| Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 2 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 1 | 1 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 6 | 1 | 7 | | 2018 | 4 | 2 | 6 | | 2019 | 2 | 2 | 4 | | 2020 | 2 | 4 | 6 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Prueitt RL, Hixon ML, Fan T, Olgun NS, Piatos P, Zhou J, Goodman JE. Systematic review of the potential carcinogenicity of bisphenol A in humans. Regul Toxicol Pharmacol. 2023 Aug; 142:105414.
-
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab. 2022 08; 24(8):1578-1587.
-
Kurtz R, Libby A, Jones BA, Myakala K, Wang X, Lee Y, Knoer G, Lo Cascio JN, McCormack M, Nguyen G, Choos END, Rodriguez O, Rosenberg AZ, Ranjit S, Albanese C, Levi M, Ecelbarger CM, Shepard BD. Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. Int J Mol Sci. 2022 May 18; 23(10).
-
Gr?nert SC, Derks TGJ, Adrian K, Al-Thihli K, Ballhausen D, Bidiuk J, Bordugo A, Boyer M, Bratkovic D, Brunner-Krainz M, Burlina A, Chakrapani A, Corpeleijn W, Cozens A, Dawson C, Dhamko H, Milosevic MD, Eiroa H, Finezilber Y, Moura de Souza CF, Garcia-Jim?nez MC, Gasperini S, Haas D, H?berle J, Halligan R, Fung LH, H?rbe-Blindt A, Horka LM, Huemer M, U?ar SK, Kecman B, Kilavuz S, Kriv?n G, Lindner M, L?sebrink N, Makrilakis K, Mei-Kwun Kwok A, Maier EM, Maiorana A, McCandless SE, Mitchell JJ, Mizumoto H, Mundy H, Ochoa C, Pierce K, Fraile PQ, Regier D, Rossi A, Santer R, Schuman HC, Sobieraj P, Spenger J, Spiegel R, Stepien KM, Tal G, Tan?ek MZ, Torkar AD, Tchan M, Thyagu S, Schrier Vergano SA, Vucko E, Weinhold N, Zsidegh P, Wortmann SB. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. Genet Med. 2022 08; 24(8):1781-1788.
-
Tommerdahl KL, Nelson RG, Bjornstad P. Dapagliflozin in young people with type 2 diabetes. Lancet Diabetes Endocrinol. 2022 05; 10(5):303-304.
-
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Kidney Effects of Empagliflozin in People with Type 1 Diabetes. Clin J Am Soc Nephrol. 2021 11; 16(11):1715-1719.
-
Rasouli N. An Escape From Diabetes. J Clin Endocrinol Metab. 2020 09 01; 105(9).
-
Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020 08 25; 142(8):734-747.
-
Samuels JM, Coleman JR, Moore EE, Bartley M, Vigneshwar N, Cohen M, Silliman CC, Sauaia A, Banerjee A. Alternative Complement Pathway Activation Provokes a Hypercoagulable State with Diminished Fibrinolysis. Shock. 2020 05; 53(5):560-565.
-
Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020 08; 22(8):1357-1368.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|